647 related articles for article (PubMed ID: 16891318)
21. Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation.
Fionda C; Soriani A; Malgarini G; Iannitto ML; Santoni A; Cippitelli M
J Immunol; 2009 Oct; 183(7):4385-94. PubMed ID: 19748980
[TBL] [Abstract][Full Text] [Related]
22. Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients.
Salih HR; Goehlsdorf D; Steinle A
Hum Immunol; 2006 Mar; 67(3):188-95. PubMed ID: 16698441
[TBL] [Abstract][Full Text] [Related]
23. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.
Diefenbach A; Hsia JK; Hsiung MY; Raulet DH
Eur J Immunol; 2003 Feb; 33(2):381-91. PubMed ID: 12645935
[TBL] [Abstract][Full Text] [Related]
24. NKG2D engagement of colorectal cancer-specific T cells strengthens TCR-mediated antigen stimulation and elicits TCR independent anti-tumor activity.
Maccalli C; Pende D; Castelli C; Mingari MC; Robbins PF; Parmiani G
Eur J Immunol; 2003 Jul; 33(7):2033-43. PubMed ID: 12884870
[TBL] [Abstract][Full Text] [Related]
25. Cytokine-driven regulation of NK cell functions in tumor immunity: role of the MICA-NKG2D system.
Zwirner NW; Fuertes MB; Girart MV; Domaica CI; Rossi LE
Cytokine Growth Factor Rev; 2007; 18(1-2):159-70. PubMed ID: 17324607
[TBL] [Abstract][Full Text] [Related]
26. Potentiation of NK cell-mediated cytotoxicity in human lung adenocarcinoma: role of NKG2D-dependent pathway.
Le Maux Chansac B; Missé D; Richon C; Vergnon I; Kubin M; Soria JC; Moretta A; Chouaib S; Mami-Chouaib F
Int Immunol; 2008 Jul; 20(7):801-10. PubMed ID: 18441340
[TBL] [Abstract][Full Text] [Related]
27. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition.
Wrobel P; Shojaei H; Schittek B; Gieseler F; Wollenberg B; Kalthoff H; Kabelitz D; Wesch D
Scand J Immunol; 2007; 66(2-3):320-8. PubMed ID: 17635809
[TBL] [Abstract][Full Text] [Related]
28. [Expression of NKG2D ligands on dendritic cells at different development stages and its effect on cytotoxicity of NK cells].
Tu SF; Guo KY; Hu LS; Mei JZ; Zhou J; Sun M
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Apr; 24(4):341-3, 347. PubMed ID: 18394338
[TBL] [Abstract][Full Text] [Related]
29. Opposing effects of interferon-alpha and interferon-gamma on the expression of major histocompatibility complex class I chain-related A in tumors.
Zhang C; Niu J; Zhang J; Wang Y; Zhou Z; Zhang J; Tian Z
Cancer Sci; 2008 Jun; 99(6):1279-86. PubMed ID: 18422748
[TBL] [Abstract][Full Text] [Related]
30. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.
Paschen A; Sucker A; Hill B; Moll I; Zapatka M; Nguyen XD; Sim GC; Gutmann I; Hassel J; Becker JC; Steinle A; Schadendorf D; Ugurel S
Clin Cancer Res; 2009 Aug; 15(16):5208-15. PubMed ID: 19671853
[TBL] [Abstract][Full Text] [Related]
31. IL-2/IL-18 prevent the down-modulation of NKG2D by TGF-beta in NK cells via the c-Jun N-terminal kinase (JNK) pathway.
Song H; Hur DY; Kim KE; Park H; Kim T; Kim CW; Bang S; Cho DH
Cell Immunol; 2006 Jul; 242(1):39-45. PubMed ID: 17070508
[TBL] [Abstract][Full Text] [Related]
32. Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity.
Groh V; Smythe K; Dai Z; Spies T
Nat Immunol; 2006 Jul; 7(7):755-62. PubMed ID: 16732291
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D.
Zhang C; Zhang J; Niu J; Zhou Z; Zhang J; Tian Z
Hum Immunol; 2008 Aug; 69(8):490-500. PubMed ID: 18619507
[TBL] [Abstract][Full Text] [Related]
34. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses.
Hilpert J; Grosse-Hovest L; Grünebach F; Buechele C; Nuebling T; Raum T; Steinle A; Salih HR
J Immunol; 2012 Aug; 189(3):1360-71. PubMed ID: 22730533
[TBL] [Abstract][Full Text] [Related]
36. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2.
Textor S; Fiegler N; Arnold A; Porgador A; Hofmann TG; Cerwenka A
Cancer Res; 2011 Sep; 71(18):5998-6009. PubMed ID: 21764762
[TBL] [Abstract][Full Text] [Related]
37. Induction of NKG2D ligands and increased sensitivity of tumor cells to NK cell-mediated cytotoxicity by hematoporphyrin-based photodynamic therapy.
Park MJ; Bae JH; Chung JS; Kim SH; Kang CD
Immunol Invest; 2011; 40(4):367-82. PubMed ID: 21314289
[TBL] [Abstract][Full Text] [Related]
38. Hypoxia downregulates the expression of cell surface MICA without increasing soluble MICA in osteosarcoma cells in a HIF-1α-dependent manner.
Yamada N; Yamanegi K; Ohyama H; Hata M; Nakasho K; Futani H; Okamura H; Terada N
Int J Oncol; 2012 Dec; 41(6):2005-12. PubMed ID: 22992985
[TBL] [Abstract][Full Text] [Related]
39. Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid.
Poggi A; Venturino C; Catellani S; Clavio M; Miglino M; Gobbi M; Steinle A; Ghia P; Stella S; Caligaris-Cappio F; Zocchi MR
Cancer Res; 2004 Dec; 64(24):9172-9. PubMed ID: 15604289
[TBL] [Abstract][Full Text] [Related]
40. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.
Ghiringhelli F; Ménard C; Terme M; Flament C; Taieb J; Chaput N; Puig PE; Novault S; Escudier B; Vivier E; Lecesne A; Robert C; Blay JY; Bernard J; Caillat-Zucman S; Freitas A; Tursz T; Wagner-Ballon O; Capron C; Vainchencker W; Martin F; Zitvogel L
J Exp Med; 2005 Oct; 202(8):1075-85. PubMed ID: 16230475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]